|
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide
|
DB04310 |
|
|
4,4'-PROPANE-2,2-DIYLDIPHENOL
|
DB06973 |
|
|
4-Phenylbutylamine
|
DB04311 |
|
|
7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile
|
DB06972 |
|
|
(2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid
|
DB06982 |
|
|
(2S)-2-(1H-indol-3-yl)pentanoic acid
|
DB06981 |
|
|
OT-551
|
DB05650 |
[OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. A leading cause of vision loss, AMD affects approximately 10 million Americans.] |
|
2-Bromo-2-Propene-1-Ol
|
DB04320 |
|
|
(2S)-2-(1H-indol-3-yl)hexanoic acid
|
DB06980 |
|
|
Isoquinoline
|
DB04329 |
|
|
Faropenem medoxomil
|
DB05659 |
[Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem]. The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.] |
|
Phosphatidylethanolamine
|
DB04327 |
|
|
Shikimate-3-Phosphate
|
DB04328 |
|
|
{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID
|
DB06989 |
|
|
Phenethylamine
|
DB04325 |
|
|
2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE
|
DB06988 |
|
|
Dihydroxyacetone phosphate
|
DB04326 |
[Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.] |
|
Veltuzumab
|
DB05656 |
[Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.] |
|
(R)-Atenolol
|
DB06987 |
|
|
2-Amino-3-(Cystein-S-Yl)-Isoxazolidin-5-Yl-Acetic Acid
|
DB04323 |
|
